Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001274173-25-000124
Filing Date
2025-05-14
Accepted
2025-05-14 11:48:25
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 7536
  Complete submission text file 0001274173-25-000124.txt   9474
Mailing Address 201 BISHOPSGATE LONDON X0 EC2M 3AE
Business Address 201 BISHOPSGATE LONDON X0 EC2M 3AE 442078181818
JANUS HENDERSON GROUP PLC (Filed by) CIK: 0001274173 (see all company filings)

EIN.: 000000000 | State of Incorp.: Y9 | Fiscal Year End: 1231
Type: SCHEDULE 13G
SIC: 6282 Investment Advice
(CF Office: 02 Finance)

Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 6508505070
Maze Therapeutics, Inc. (Subject) CIK: 0001842295 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94841 | Film No.: 25943763
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)